Uppsala 2022-03-24

DBP International: Positive opinion in international phase (PCT) of patent application for iron succinate

Double Bond Pharmaceutical International AB (publ) ("DBP") is pleased to announce a positive written opinion regarding their international patent application relating to iron succinate (Inofer) for treatment of patients diagnosed with heart failure with reduced ejection fraction (HFrEF). The application enters the national phase in May 2022.

The results of clinical trials undertaken by DBP indicate that ferrous succinate ("Inofer") markedly and significantly improved iron uptake, iron saturation, and iron stores in patients with heart failure and iron deficiency.

Inofer is a low-cost oral alternative to a widely sold product called FerInject (which is, as its name indicates, administered intravenously). In 2020, FerInject reported global net sales of US$550 million.

More about the clinical study of Iron Succinate:
https://mb.cision.com/Main/12720/2974295/1151389.pdf,
https://www.scirp.org/journal/paperinformation.aspx?paperid=106484

More about the patent application of Iron Succinate:
https://mb.cision.com/Main/12720/2975083/1151998.pdf,
https://mb.cision.com/Main/12720/3240622/1337718.pdf

Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Follow us on LinkedIn and Twitter!

Information about Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on the development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumors, in October 2015, and was granted Orphan Drug Designation status by EMA in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in the EU and globally and has a working name SI-053 in the DBP pipeline.